MOTS-c oral dissolving strips represent a specialized transmucosal delivery matrix engineered for in vitro and preclinical research evaluating mitochondrial-derived peptide pharmacokinetics. Designed to bypass traditional digestive degradation, this solid-state formulation allows researchers to study sublingual and buccal absorption dynamics, metabolic signaling, and nuclear translocation of the MOTS-c peptide in laboratory models.
MOTS-c oral dissolving strips represent a specialized transmucosal delivery matrix engineered for in vitro and preclinical research evaluating mitochondrial-derived peptide pharmacokinetics. Designed to bypass traditional digestive degradation, this solid-state formulation allows researchers to study sublingual and buccal absorption dynamics, metabolic signaling, and nuclear translocation of the MOTS-c peptide in laboratory models.
MOTS-c oral dissolving strips are a fast-dissolving transmucosal vehicle formulated to deliver the mitochondrial-derived peptide (MDP) MOTS-c across mucosal membranes in laboratory test systems. Encoded within the 12S ribosomal RNA gene of the mitochondrial genome, MOTS-c is a 16-amino-acid peptide that operates as an endocrine-like signal, translocating to the nucleus during cellular metabolic stress to regulate nuclear gene expression, glucose utilization, and fatty acid oxidation.
Traditional preclinical research involving research peptides often relies on parenteral administration (such as subcutaneous or intraperitoneal injection) or liquid reconstitution, which can introduce variance in systemic bioavailability due to rapid enzymatic degradation in digestive fluids. The development of oral dissolving strip matrices provides an alternative model for investigating non-invasive transmucosal absorption, mucosal tissue permeability, and immediate-release kinetics without requiring liquid dilution steps prior to administration in specialized testing protocols.
Researchers utilize mots-c oral dissolving strips primarily to evaluate how transmucosal delivery impacts peptide stability, systemic absorption dynamics, and target tissue bio-distribution in rodent and cell culture models. By maintaining a stable, solid polymer matrix that rapidly disintegrates upon mucosal contact, laboratories can standardize dosage delivery while minimizing baseline hydrolysis.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) possesses the unique primary amino acid sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MW ~2174.6 g/mol). Unlike classic nuclear-encoded peptides, MOTS-c is derived directly from the mitochondrial genome, representing a crucial communication axis between mitochondria and the host cell nucleus.
In cell culture models under basal metabolic conditions, MOTS-c primarily localizes within the cytoplasm and mitochondrial matrix. However, upon exposure to metabolic stressors—such as nutrient restriction, oxidative strain, or glucose depletion—MOTS-c translocates to the nucleus. This translocation is mediated by activation of the p38 mitogen-activated protein kinase (p38 MAPK) pathway, enabling the peptide to bind directly to nuclear chromatin and regulate adaptive metabolic transcriptional programs.
Integrating MOTS-c into a polymeric strip matrix requires rigorous physical chemistry controls to preserve the structural integrity of its terminal arginine and lysine residues. Unformulated peptides exposed to saliva or gastric fluids are subject to rapid cleavage by peptidases like trypsin and carboxypeptidases. The water-soluble polymer matrix used in research-grade oral dissolving strips encapsulates the peptide, protecting it until mucosal dissolution occurs.
Preclinical studies indicate that MOTS-c plays a central role in metabolic homeostasis by modulating the 5'-AMP-activated protein kinase (AMPK) signaling pathway. In vitro assays demonstrate that MOTS-c indirectly promotes AMPK phosphorylation by inhibiting the folate-methionine cycle. This inhibition leads to a temporary depletion of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase activity, resulting in intracellular accumulation of the endogenous AMPK activator AICAR.
Downstream effects of MOTS-c-mediated AMPK activation in animal models include enhanced glucose transporter 4 (GLUT4) translocation to cell membranes, elevated rate of fatty acid beta-oxidation, and suppression of de novo lipogenesis. Furthermore, MOTS-c signaling has been shown in rodent assays to improve skeletal muscle insulin sensitivity, independent of systemic insulin secretion.
In exercise-capacity research models, administration of MOTS-c has been associated with increased treadmill run time, improved oxygen consumption (VO2 max markers), and enhanced mitochondrial biogenesis via upregulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). Investigating these signaling cascades via mots-c oral dissolving strips allows researchers to observe whether mucosal absorption yields comparable target tissue activation relative to conventional injection methods.
A critical area of investigation in peptide pharmacokinetics is overcoming the low oral bioavailability characteristic of hydrophilic macromolecules. Standard oral gavage of unencapsulated MOTS-c results in near-total degradation by stomach acid and pepsin, alongside significant first-pass hepatic metabolism.
Oral dissolving strips utilize bioadhesive, hydrophilic polymers (such as hydroxypropyl methylcellulose or pullulan) that adhere to the buccal or sublingual mucosa. Upon hydration by mucosal secretions, the matrix disintegrates within seconds, releasing the MOTS-c peptide directly into the capillary-rich mucosal microvasculature. Preclinical assays evaluating transmucosal penetration suggest that this route bypasses the gastrointestinal tract and first-pass hepatic extraction, yielding distinct plasma concentration curves compared to subcutaneous administration.
For research environments, solid transmucosal strips eliminate the immediate need for sterile reconstitution solutions like bacteriostatic water at the point of administration. This reduces handling variability, eliminates potential microbial contamination during liquid dilution, and offers precise mass uniformities per strip unit across multi-subject animal cohorts.
To contextualize MOTS-c within mitochondrial energetics research, laboratories often compare its mechanism against other mitochondrial-targeted compounds. While MOTS-c functions primarily as a nuclear-translocating metabolic signaling peptide, alternative compounds act through distinct biophysical or receptor-mediated mechanisms.
For example, SS-31 (Elamipretide) targets the inner mitochondrial membrane directly, selectively binding to cardiolipin to optimize electron transport chain efficiency and diminish electron leakage. In contrast, Humanin is another mitochondrial-derived peptide that focuses predominantly on cytoprotection, binding to Bax to prevent apoptotic signaling during ischemic or oxidative stress. Meanwhile, non-peptidyl metabolic modulators like GW501516 target nuclear receptors directly (PPAR-δ) to shift substrate utilization toward lipid oxidation without interacting with the mitochondrial ribosomal encoding machinery.
The following matrix summarizes the comparative operational profiles of these research compounds within laboratory models:
Maintaining rigorous quality standards is essential when utilizing peptide matrices in quantitative research assays. Impurities, peptide truncations, or residual endotoxins can distort cellular signaling data, mask target enzyme interactions, or induce non-specific inflammatory responses in preclinical animal models.
At PX1 Research, every production lot of mots-c oral dissolving strips undergoes extensive analytical verification in an ISO 17025 accredited laboratory environment. High-Performance Liquid Chromatography (RP-HPLC) is conducted to confirm chromatographic purity exceeding 98.0%, ensuring the absence of deletion sequences or degradation products. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular mass (2174.6 Da) of the synthetic MOTS-c sequence.
Furthermore, because oral dissolving strips incorporate polymer matrices alongside active peptide ingredients, endotoxin testing via Limulus Amebocyte Lysate (LAL) assays is mandatory. PX1 Research enforces strict limits, ensuring endotoxin levels remain under 0.01 EU/mg to eliminate confounding immune responses in delicate cellular or animal assays. Full Certificate of Analysis (COA) documentation detailing lot-specific purity, mass spectral data, and dissolution metrics is publicly accessible via our research documentation hub.
The structural stability of MOTS-c within a solid polymer film depends heavily on moisture content, ambient temperature, and light exposure. Unlike lyophilized powders stored in sealed glass vials, polymer strips absorb atmospheric humidity if left exposed, which can initiate premature peptide degradation or loss of film elasticity.
In vitro dissolution testing of research-grade strips is typically performed using USP Dissolution Apparatus formats filled with phosphate-buffered saline (PBS, pH 7.4) at 37°C. Under standardized laboratory conditions, high-purity strips exhibit complete matrix disintegration within 15 to 45 seconds, releasing >95% of the active MOTS-c peptide payload into solution within 2 minutes.
To preserve matrix stability, strips should be stored in desiccated, light-resistant foil packaging at controlled temperatures (-20°C for long-term storage; 2°C to 8°C for active trial protocols). Researchers handling the material should allow unopened packages to equilibrate to ambient room temperature prior to opening to prevent atmospheric condensation from accumulating on the strip surface.
Procuring standardized peptides for institutional, academic, or private research facilities requires working with suppliers that uphold transparent manufacturing and analytical verification processes. PX1 Research synthesizes and manufactures all compounds within GMP-compliant, USA-based facilities, ensuring strict lot-to-lot consistency and complete traceability.
Research teams establishing ongoing study protocols can register for institutional access through our wholesale laboratory portal. All orders ship directly from our centralized distribution hubs in California and Arizona, utilizing fast, temperature-managed dispatch protocols (same-day shipping Monday through Friday) to preserve peptide stability during transit.
Whether evaluating metabolic signal transduction, mitochondrial biogenesis, or transmucosal drug delivery dynamics, researchers can source verified mots-c oral dissolving strips backed by lot-specific COAs, HPLC chromatograms, and mass spectra directly from the PX1 Research catalog.
What is the primary operational advantage of MOTS-c oral dissolving strips over liquid formulations?
MOTS-c oral dissolving strips provide a solid-state, pre-measured delivery matrix designed for transmucosal absorption studies. This format eliminates the need for liquid reconstitution prior to handling, prevents rapid gastric hydrolysis encountered in oral gavage models, and minimizes dosing volume variability across preclinical subjects.
How does MOTS-c regulate cellular metabolism in research models?
Preclinical data show that MOTS-c activates the AMPK signaling pathway indirectly by inhibiting the folate-methionine cycle, leading to AICAR accumulation. Activated AMPK promotes GLUT4 translocation, enhances mitochondrial biogenesis via PGC-1α, and increases fatty acid beta-oxidation in cell and animal models.
Are PX1 Research MOTS-c strips tested for purity and endotoxins?
Yes. Every batch of MOTS-c oral dissolving strips manufactured by PX1 Research undergoes independent third-party testing in an ISO 17025 accredited laboratory. Purity is verified via RP-HPLC (>98.0%), molecular identity is confirmed via ESI-MS, and endotoxin levels are measured via LAL assay to guarantee values below 0.01 EU/mg.
How should MOTS-c oral dissolving strips be stored in the laboratory?
Strips should be kept in their original sealed, desiccated foil packaging. For long-term storage, maintain temperatures at -20°C. For active daily protocols, storage at 2°C to 8°C is acceptable. Always allow sealed packages to reach room temperature before opening to avoid moisture condensation.
What is the typical in vitro dissolution rate of these research strips?
In standard phosphate-buffered saline (PBS, pH 7.4) at 37°C, PX1 Research oral dissolving strips disintegrate within 15 to 45 seconds, achieving complete active peptide release into the medium within 120 seconds.
Can MOTS-c strips be used for human consumption or clinical therapy?
No. MOTS-c oral dissolving strips supplied by PX1 Research are strictly for in vitro, biochemical, and preclinical laboratory research use only. They are not approved for human consumption, therapeutic use, or clinical administration.
What analytical documents are provided with institutional orders?
Every shipment includes a lot-specific Certificate of Analysis (COA) containing RP-HPLC purity chromatograms, mass spectrometry (ESI-MS) spectra, moisture content analyses, and LAL endotoxin verification data.
How does MOTS-c differ mechanism-wise from SS-31 or Humanin?
MOTS-c acts primarily as a nuclear-translocating transcriptional regulator of metabolic homeostasis via AMPK. SS-31 binds directly to cardiolipin in the inner mitochondrial membrane to optimize electron transport efficiency, while Humanin acts primarily as a cytoprotective peptide inhibiting Bax-mediated apoptotic pathways.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.